Emerging treatments for pyoderma gangrenosum

References

• Wollina U. Pyoderma gangrenosum–a review. Orphanet J Rare Dis. 2007;2:19.
   Google Scholar
• Langan SM, Groves RW, Card TR, et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132(9):2166–2170.
   Google Scholar
• Wollina U. Pyoderma gangrenosum–a systemic disease?. Clin Dermatol. 2015;33(5):527–530.
   Google Scholar
• Al Ghazal P, Herberger K, Schaller J, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013 Sep 8;8:136.
   Google Scholar
• Adışen E, Erduran F, Gürer MA. Pyoderma gangrenosum: a report of 27 patients. Int J Low Extrem Wounds. 2016;15(2):148–154.
   Google Scholar
• Anuset D, Reguiai Z, Perceau G, et al. Clinical patterns and treatment of pyoderma gangrenosum in a French department. Ann Dermatol Venereol. 2016;143(2):108–117.
   Google Scholar
• Wollina U, Haroske G. Pyoderma gangraenosum. Curr Opin Rheumatol. 2011;23(1):50–56.
   Google Scholar
• Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149(6):762–764.
   Google Scholar
• Marzano AV, Borghi A, Meroni PL, et al. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016;175(5):882–891.
   Google Scholar
• Gurung P, Kanneganti TD. Autoinflammatory skin disorders: the inflammasomme in focus. Trends Mol Med. 2016;22(7):545–564.
   Google Scholar
• Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178(1):48–56.
   Google Scholar
• Antiga E, Maglie R, Volpi W, et al. T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum. Clin Exp Immunol. 2017;189(3):383–391.
   Google Scholar
• Caproni M, Antiga E, Volpi W, et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol. 2015;173(1):275–278.
   Google Scholar
• Marzano AV, Cugno M, Trevisan V, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010;162(1):100–107.
   Google Scholar
• Quaglino P, Fava P, Caproni M, et al. Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group. J Eur Acad Dermatol Venereol. 2016;30(4):655–658.
   Google Scholar
• Marzano AV, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017;176(6):1588–1598.
   Google Scholar
• Marzano AV, Ceccherini I, Gattorno M, et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore). 2014;93(27):e187.
   Google Scholar
• Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3(3):149–158.
   Google Scholar
• Mason JM, Thomas KS, Ormerod AD, et al. U.K. Dermatology Clinical Trials Network’s STOP GAP team. Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. Br J Dermatol. 2017. doi:10.1111/bjd.15561. [Epub ahead of print].
   Google Scholar
• Wollina U, Tchernev G. Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr. 2014;164(13–14):263–273.
   Google Scholar
• Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, et al. Kachroo S. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15(1):25–36.e27.
   Google Scholar
• Groleau PF, Grossberg AL, Gaspari AA. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated with infliximab. Cutis. 2015;95(6):337–342.
   Google Scholar
• Saraceno R, Babino G, Chiricozzi A, et al. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. J Am Acad Dermatol. 2015;72(1):e42–4.
   Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434.
   Google Scholar
• Benzaquen M, Monnier J, Beaussault Y, et al. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: effectiveness of ustekinumab. Australas J Dermatol. 2017. Epub ahead of print. DOI:10.1111/ajd.12545
   Google Scholar
• Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161(5):1199–1201.
   Google Scholar
• Lin Z, Hegarty JP, Lin T, et al. Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene. Inflamm Bowel Dis. 2011;17(6):E41–2.
   Google Scholar
• Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)–a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66(3):409–415.
   Google Scholar
• Jennings L, Molloy O, Quinlan C, et al. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier. Int J Dermatol. 2017;56(6):e128–e129.
   Google Scholar
• Zeeli T, Padalon-Brauch G, Ellenbogen E, et al. Pyoderma gangrenosum, acne and ulcerative colitis in a patient with a novel mutation in the PSTPIP1 gene. Clin Exp Dermatol. 2015;40(4):367–372.
   Google Scholar
• Acquitter M, Plantin P, Kupfer I, et al. Anakinra improves pyoderma gangrenosum in psoriatic arthritis: a case report. Ann Intern Med. 2015;163(1):70–71.
   Google Scholar
• Leuenberger M, Berner J, Di Lucca J, et al. PASS syndrome: an IL-1-driven autoinflammatory disease. Dermatology. 2016;232(2):254–258.
   Google Scholar
• Beynon C, Chin MF, Hunasehally P, et al. Successful treatment of autoimmune disease-associated pyoderma gangrenosum with the IL-1 receptor antagonist anakinra: a case series of 3 patients. J Clin Rheumatol. 2017;23(3):181–183.
   Google Scholar
• Kolios AG, Maul JT, Meier B, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015;173(5):1216–1223.
   Google Scholar
• Galimberti RL, Vacas AS, Bollea Garlatti ML, et al. The role of interleukin-1β in pyoderma gangrenosum. JAAD Case Rep. 2016;2(5):366–368.
   Google Scholar
• Jaeger T, Andres C, Grosber M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa–rapid response to canakinumab (anti-IL-1β). Eur J Dermatol. 2013;23(3):408–410.
   Google Scholar
• Geusau A, Mothes-Luksch N, Nahavandi H, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 2013;149(2):209–215.
   Google Scholar
• Lopalco G, Rigante D, Giannini M, et al. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin Exp Rheumatol. 2016;34(3):531–538.
   Google Scholar
• Swart JF, Barug D, Möhlmann M, et al. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther. 2010;10(12):1743–1752.
   Google Scholar
• European Union 2016; Available from: https://ec.europa.eu/health/documents/community-register/2016/20160602135155/anx_135155_de.pdf (Last accessed on 2017 Jul 16).
   Google Scholar
• Ruperto N, Quartier P, Wulffraat N, et al. Paediatric rheumatology international clinical trials organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64(2):557–567.
   Google Scholar
• Wulffraat NM. A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis. Expert Opin Drug Saf. 2015;14(12):1961–1967.
   Google Scholar
• Fasching P, Stradner M, Graninger W, et al. Therapeutic potential of targeting the Th17/Treg axis in autoimmune disorders. Molecules. 2017;22(1):pii: E134.
   Google Scholar
• Lee Y, Kuchroo V. Defining the functional states of Th17 cells. F1000Research. 2015;4:1–7.
   Google Scholar
• Greb JE, Gottlieb AB, Goldminz AM. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. Dermatol Ther. 2016;29(6):482–483.
   Google Scholar
• Fahmy M, Ramamoorthy S, Hata T, et al. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012;107(5):794–795.
   Google Scholar
• Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147(10):1203–1205.
   Google Scholar
• Roman M, Madkan VK, Chiu MW. Profile of secukinumab in the treatment of psoriasis: current perspectives. Ther Clin Risk Manag. 2015;11:1767–1777.
   Google Scholar
• Syed YY. Ixekizumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2017;18(1):147–158.
   Google Scholar
• Tong Y, Peranteau AJ, Nawas Z, et al. A review of brodalumab, an IL-17 receptor antagonist, for moderate-to-severe plaque psoriasis. Skin Therapy Lett. 2017;22(1):1–6.
   Google Scholar
• Mease PJ, Van Der Heijde D, Ritchlin CT, et al.; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87.
   Google Scholar
• Ryoo JY, Yang HJ, Ji E, et al. Meta-analysis of the efficacy and safety of secukinumab for the treatment of plaque psoriasis. Ann Pharmacother. 2016;50(5):341–351.
   Google Scholar
• Sakkas LI, Mavropoulos A, Bogdanos DP. Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives. Curr Med Chem. 2017. Epub ahead of print. DOI:10.2174/0929867324666170530093902
   Google Scholar
• Chimenti MS, Gramiccia T, Saraceno R, et al. Apremilast for the treatment of psoriasis. Expert Opin Pharmacother. 2015;16(13):2083–2094.
   Google Scholar
• Laird ME, Tong LX, Lo Sicco KI, et al. Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum. JAAD Case Rep. 2017;3(3):228–229.
   Google Scholar
• Dattola A, Del Duca E, Saraceno R, et al. Bianchi L Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017;16(3):381–385.
   Google Scholar
• Rogliani P, Calzetta L, Cazzola M, et al. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opin Drug Saf. 2016;15(8):1133–1146.
   Google Scholar
• Chokoeva AA, Cardoso JC, Wollina U, et al. Pyoderma gangrenosum - a novel approach? Wien Med Wochenschr. 2017;167(3–4):58–65.
   Google Scholar